Dr Masood Moghul speaks to ecancer about the man van phase 2 study results.

This study on mobile targeted case finding for prostate cancer reveals significant advancements in patient recruitment and diagnostic rates.

The second phase improved patient throughput while ensuring ethnic diversity, with nearly 40% of participants being non-white.

The diagnostic rate for prostate cancer reached 3.11%, primarily identifying clinically significant cases.

A new method for targeting underserved populations was developed, enhancing healthcare access and addressing disparities in health outcomes.

Read the related news story here.